Literature DB >> 32838039

One world, one health: The novel coronavirus COVID-19 epidemic.

José Luis Callejas Rubio1, Raquel Ríos Fernández1, Norberto Ortego Centeno1.   

Abstract

Entities:  

Year:  2020        PMID: 32838039      PMCID: PMC7377713          DOI: 10.1016/j.medcle.2020.05.008

Source DB:  PubMed          Journal:  Med Clin (Engl Ed)        ISSN: 2387-0206


× No keyword cloud information.
To the Editor: We have read the magnificent editorial by Trilla A. recently published in your journal on the coronavirus COVID-19 epidemic. We understand that the author's intention, as a specialist in preventive medicine and epidemiology, has not been to review the different clinical aspects of SARS-CoV-2 infection, regarding which we are sure that there will be plenty of time to write extensively about it in the coming months in this prestigious publication, as well as about the different treatments used. But what can be inferred from its reading, especially by readers who are not involved in the diagnosis, clinical monitoring and treatment of this disease, is that it is a purely an infectious disease, which basically produces a viral condition that can be complicated by a more or less severe pneumonia with respiratory distress, and whose treatment is based on the use of antiviral drugs. Nothing could be further from the truth. From a clinical point of view, the clinical manifestations can be truly diverse, and could practically involve any system or organ of our anatomy.2, 3, 4 From a therapeutic point of view, and with the idea of preventing another very serious complication of this infection, such as a cytokine storm syndrome, besides the use of antivirals, the use of immunomodulatory and immunosuppressive drugs is essential. Therefore, SARS-CoV-2 infection represents, in our opinion, the paradigm of a systemic disease, with an infectious trigger, in this case, the virus, and an immune response with systemic manifestations, which requires the use of an immunosuppressant treatment.
  5 in total

1.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

2.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.

Authors:  Tomasz J Guzik; Saidi A Mohiddin; Anthony Dimarco; Vimal Patel; Kostas Savvatis; Federica M Marelli-Berg; Meena S Madhur; Maciej Tomaszewski; Pasquale Maffia; Fulvio D'Acquisto; Stuart A Nicklin; Ali J Marian; Ryszard Nosalski; Eleanor C Murray; Bartlomiej Guzik; Colin Berry; Rhian M Touyz; Reinhold Kreutz; Dao Wen Wang; David Bhella; Orlando Sagliocco; Filippo Crea; Emma C Thomson; Iain B McInnes
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

Review 3.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Cristina Belizna; Albert Selva-O'Callaghan; Josep Pardos-Gea; Angela Quintana; Arsene Mekinian; Ariadna Anunciacion-Llunell; Francesc Miró-Mur
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

4.  Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes.

Authors:  Chaoqun Han; Caihan Duan; Shengyan Zhang; Brennan Spiegel; Huiying Shi; Weijun Wang; Lei Zhang; Rong Lin; Jun Liu; Zhen Ding; Xiaohua Hou
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

5.  One world, one health: The novel coronavirus COVID-19 epidemic.

Authors:  Antoni Trilla
Journal:  Med Clin (Engl Ed)       Date:  2020-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.